Top Neurotech Stocks 2026: Brain Implants Go Public

The most famous neurotech company in the space (Neuralink) is private. The second most famous is private. So is the third.

And the ones you can buy? Most of them have been quietly selling brain implants for 20 years. They just never called it "neurotech."

So, let's start with the definition. Neurotech is any device that reads signals from the nervous system, writes signals into it, or both.^[1] That covers three very different things:

1. Neuromodulation. Pacemakers for the brain and nerves. Deep brain stimulation for Parkinson's, vagus nerve stimulation for epilepsy, spinal cord stimulation for pain. Boring. Profitable. Approved.
2. Brain-computer interfaces (BCI). Read a paralyzed person's motor cortex, turn it into a cursor. This is the Neuralink stuff. Experimental. Unprofitable. Not approved in the U.S.
3. Consumer neural wearables. Wristbands and headbands that read nerve or brain signals from outside the body. Meta shipped one. It's a game controller.

Sentiment right now is lopsided. Morgan Stanley put a $400 billion number on the BCI opportunity, and we've seen the video of a paralyzed man playing Mario Kart with his mind. Meanwhile, the actual BCI device market is about $1.3 billion in 2026, growing around 15% a year. That's a rounding error next to the hype.

Neuralink's valuation went up roughly 4x in a year while its patient count went from 12 to 21. Nothing about the technology changed that fast. What changed: SpaceX went public in June 2026, and everyone who missed it started bidding for the next Musk company.

The sexiest neurotech companies can't be bought. The buyable ones aren't sexy. Pick your poison.

The first FDA premarket approval for a decoding BCI probably lands in 2027, not 2026.^[2] When it does, the winners will be the companies that already own the surgeons, the hospital contracts, and the navigation tools those surgeons use.

That's why we slice this list five ways:

• Incumbents: Big medtech that already sells approved neural implants and is bolting BCI features onto them.
• Pure-play: Small caps whose entire business is a neural device.
• Picks-and-shovels: Companies that get paid regardless of which implant wins.
• Big Tech: Consumer platforms turning neural signals into an input method.
• Private: The bellwethers that will define the space once they list.

These companies were "neurotech" before it was a Google search. They sell approved implants, bill insurance, and generate cash. The bet here is that they buy BCI, license it, or make it a feature.

Medtronic NYSE: MDT

If one company already owns the neurotech surgeon, it's Medtronic. Its deep brain stimulation systems have been going into Parkinson's patients for 30 years.

What makes it a neurotech stock rather than a medtech stock: BrainSense Adaptive. In February 2025 the FDA approved Medtronic's Percept system to read a patient's own brain signals and adjust stimulation in real time. That's a closed-loop brain-computer interface, sold commercially, at scale. Medtronic says it's the only company with one. Then in January 2026 it partnered with Precision Neuroscience to pair Precision's surface electrode array with Medtronic's StealthStation surgical navigation. Translation: when a next-gen BCI needs a hospital channel, Medtronic already has the badge.

You're buying a $100B+ diversified medtech company here. Neurotech won't move the stock in 2026.

Boston Scientific NYSE: BSX

Boston Scientific is the other big DBS player, and it's the acquirer in the room. Its Vercise DBS platform competes directly with Medtronic. Its WaveWriter spinal cord stimulators own a big chunk of the pain market. And it bought Axonics in 2024 to add sacral neuromodulation for bladder control.

The pattern: Boston Scientific finds a proven neural device with a sales force and buys it. When one of the private BCIs in this list needs a commercial exit, this is a name on the shortlist. Same caveat as Medtronic though. It's a giant, and neuro is one slice.

LivaNova NASDAQ: LIVN

LivaNova is the smallest incumbent and the most "neuro" of the three. Its vagus nerve stimulator is a decades-old treatment for drug-resistant epilepsy, and business is good: neuromodulation revenue hit $166.9 million in Q2 2026, up 10%, and the company raised full-year guidance to 8–9% growth. Improved reimbursement and new clinical evidence are pushing doctors to prescribe VNS earlier.

LivaNova's next-generation pulse generator is in development, and it has a hypoglossal nerve stimulator for sleep apnea on the way. It also carries a large legacy environmental liability in Italy that you should read about before buying. Neuro is roughly 40% of revenue, which makes it more of a pure bet than the giants.

Companies where the neural device is the company. Fewer than you'd think exist on U.S. exchanges. One stands out.

NeuroPace NASDAQ: NPCE

Fun fact: the only publicly traded company selling an FDA-approved brain implant that reads neural activity and responds to it is not Neuralink. It's NeuroPace.

Its RNS System sits under the skull, monitors the brain for the electrical signature of a seizure, and zaps it before it happens. That is, functionally, a closed-loop BCI, and it's been approved since 2013. RNS revenue grew 21% in Q2 2026, and the company raised full-year guidance to $99.5–101.5 million. It just launched an AI tool called ECoG Assistant that helps doctors read the brain data the device collects.

Now the bad news. NeuroPace spent two years running the NAUTILUS trial to expand the label into idiopathic generalized epilepsy, a much bigger patient pool. In August the FDA said the submission was not approvable in its current form. The timeline is now uncertain. Guidance already excluded IGE, so the base business is intact. But the stock was priced for the upside.

At about $100 million in revenue, this is a small cap. It moves. Treat it accordingly.

Doesn't matter which implant wins. Somebody has to get it into the right spot in the brain, and somebody has to sell the hospital the tools to do it.

ClearPoint Neuro NASDAQ: CLPT

ClearPoint Neuro makes the MRI-guided navigation system neurosurgeons use to place things in the brain with sub-millimeter precision: DBS leads, laser catheters, gene-therapy infusions, and yes, BCI electrodes. Its investor decks have listed "brain computer interface navigation" as a growth pillar for years.

Every new neural implant needs a surgeon to hit a target the size of a pea. ClearPoint gets paid per procedure and per disposable, plus it's the drug-delivery partner for over 60 biopharma trials targeting the brain.

The catch showed up in August 2026: the company cut full-year revenue guidance to $48–52 million from $52–56 million, because biopharma partners bought fewer trial kits than expected. Cash was $35.6 million at the end of Q1, and it's spending on a new manufacturing facility. This is the highest-risk name on the public side of this list. It's also the one with the cleanest "shovel" story.

Not medical. Not implanted. But if you want to know where neural signals become a mass-market product, look here.

Meta NASDAQ: META

In September 2025, Meta shipped the Neural Band alongside its display glasses. It reads motor-nerve signals at the wrist using surface EMG, built on the CTRL-Labs acquisition from 2019. You can walk into a store and buy it, which makes it the only consumer neural interface on the market.

It doesn't read your brain. It reads the signals your brain sends to your hand. But it means Meta is training its models on millions of hours of real neural data from real people, and nobody else has that. Neurotech is a rounding error in Meta's numbers. This is a long-term optionality play inside a stock you'd buy for other reasons anyway.

Apple NASDAQ: AAPL

Apple made the plumbing for BCIs. In 2025 it published a BCI Human Interface Device protocol, a standard that lets an implant act as a native input for iPhone, iPad, Mac, and Vision Pro. Synchron was the first company to integrate with it.

Whoever wins the implant race still has to plug into a computer. Apple just made itself the default. Zero revenue impact today. Enormous strategic position tomorrow.

This is where the real neurotech story lives. BCI funding across 2024 and 2025 passed $1 billion, and 2026 is bigger. Merge Labs (Sam Altman, ultrasound-based, $252M from OpenAI in January at an $850M valuation), Motif Neurotech (a blueberry-sized stimulator for depression, FDA trial approved in April), Blackrock Neurotech (majority-owned by Tether, the stablecoin company) and BrainCo (China's non-invasive leader, $1.3B valuation, IPO filed) are all worth knowing. These five matter most.

Neuralink (Private)

Twenty-one patients across four countries. Two FDA Breakthrough designations. A trial to control a robotic arm, a thought-to-text speech trial, and a vision-restoration implant called Blindsight that Musk has promised will go into a human "in 2026" several times now. Neuralink raised $650 million at $9 billion in June 2025.

Then SpaceX went public in June 2026 and demand for Musk's remaining private companies went vertical. Secondary trades since have valued Neuralink between $29 billion and $42 billion, with some bids reportedly as high as $60 billion.^[3] Musk has said there are no IPO plans. If that holds, the first shares available to you will trade at a price set by people who couldn't get into SpaceX. Be careful.

Synchron (Private)

The tortoise. Synchron's Stentrode goes in through the jugular vein and sits inside a blood vessel over the motor cortex. No open-skull surgery. Fewer electrodes, lower bandwidth, but it's been in humans since 2019 with no serious device-related adverse events.

It raised $200 million in November 2025 specifically to run a pivotal trial in 2026, the one that leads to FDA premarket approval. Nobody else is at that stage. Backers include Bezos, Gates, Khosla, and the Qatar Investment Authority. If a U.S. BCI gets approved for sale first, this is the favorite. It's also the one an incumbent like Medtronic or Boston Scientific would most plausibly acquire.

Precision Neuroscience (Private)

Co-founded by a Neuralink co-founder, Precision went the opposite direction: a film thinner than a hair that lies on the brain's surface instead of poking into it. It got FDA 510(k) clearance in April 2025 to implant the array for up to 30 days, which makes it the first of this group with a cleared product.

The 30-day limit means it's a mapping tool today. But the January 2026 Medtronic partnership gives it a surgical channel most startups spend a decade building. First permanent wireless implant is expected this year.

Paradromics (Private)

If Neuralink is the loud one and Synchron is the careful one, Paradromics is the one that argues with everyone about bandwidth. Its Connexus implant packs more electrodes than any competitor and it's aimed squarely at restoring speech for people who can't talk. The FDA approved its first clinical study in November 2025. It's behind Neuralink and Synchron on patients. It may be ahead on data rate, which is what speech decoding actually needs.

Neuracle SSE STAR: pending

Most U.S. investors have never heard of this one. While American companies race for the first FDA approval, Neuracle already got one. In China. Its NEO device, a coin-sized electrode placed under the skull but outside the brain's protective membrane, received Chinese market approval in March 2026. It was prescribed commercially for the first time at a Shanghai hospital in July.

China named brain-computer interfaces a "future industry" in its 2026 government work report, several provinces have set insurance pricing for BCI procedures, and Neuracle has filed for a Shanghai STAR Market listing. Getting exposure as a U.S. retail investor will be hard. But this is the first pure-play implantable BCI that will trade anywhere, and it will set the comps.

Two ways.

The implant stops working. Every electrode in living tissue faces the same enemy: your immune system. Scar tissue builds up, signals degrade, and a device that worked beautifully at month three is mediocre at year three. Neuralink's first patient had threads retract within weeks. It fixed the surgical technique, but long-term signal stability across hundreds of patients is unproven for every company on this list. Watch for: multi-year signal data in Synchron's pivotal trial, and anything Neuralink publishes in a peer-reviewed journal.

Approval comes, revenue doesn't. Even after the FDA says yes, someone has to pay. NeuroPace has had an approved device since 2013 and still isn't profitable. Insurance coverage for a $100,000+ elective brain surgery with no reimbursement code isn't automatic. Watch for: CMS coverage decisions and the first BCI billing codes. China set prices before approval. The U.S. hasn't.

The next 12–18 months are the busiest in the sector's history. Catalysts, in rough order:

• Synchron's pivotal trial enrolls. First data readout likely 2027. This is the gating event for the entire U.S. BCI thesis.
• Neuracle and BrainCo list in Shanghai or Hong Kong. You'll get the first public valuation of a pure BCI company. Expect it to be high.
• Neuralink's Blindsight goes into a human, and the company submits its PRIME study to a major medical journal. Also watch for a new funding round. Reports had it targeting $12–15 billion before the SpaceX IPO reset everyone's math.
• NeuroPace's FDA meeting on generalized epilepsy. A path forward doubles its addressable market. A dead end takes the stock back to a slow-growth device story.
• The first BCI acquisition. Medtronic and Boston Scientific have both signaled they'll buy rather than build. Precision is the obvious target; Synchron is the expensive one.
• Meta's Neural Band sales numbers, if it ever breaks them out. Consumer adoption of neural input tells you whether this stays medical or goes mainstream.

Our job is to own the channel now and be first in line when that changes.